AstraZeneca Focus On China, Emerging Markets, Not Acquisitions
This article was originally published in PharmAsia News
Executive Summary
U.K.-based AstraZeneca plans to take a path to growth that is different from most of its global competitors; shun acquisitions and concentrate on China. CEO David Brennan says his company does not need a merger or a major acquisition to fare well in the pharmaceutical marketplace, unlike other companies about to participate in another merger mania. Mergers often are considered the best response to periods when drug pipelines are diminished by products losing patent protection. Brennan believes a better response is a focus on reducing costs at home and looking to emerging markets for sales and to instigate innovation. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.